… during EGFR-TKI treatment (250 mg daily gefitinib or 150 mg daily erlotinib) between April
… Two of the 15 patients received gefitinib and erlotinib treatment; therefore, we analyzed 17 …

… kinase inhibitor erlotinib in athymic nude mice bearing non-small cell lung cancer (NSCLC) …
At the end of this study (day 47 post-tumor implantation, treatment day 19), erlotinib 100 mg/…

… Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small
cell lung cancer (… for treatment of locally advanced, inoperable, or metastatic pancreatic …

… ) mutations have been associated with tumor response to treatment with single-agent EGFR
… small-cell lung cancer (NSCLC). The implications of EGFR mutations in patients treated with …

… Approximately 85 to 90% of all cases of lung cancer are non–small-cell lung cancer (NSCLC).
Advanced-stage NSCLC is currently considered an incurable disease for which standard …

… Median survival for patients treated with erlotinib was 10.6 v 10.5 months for placebo (hazard
ratio, 0.99; 95% CI, 0.86 to 1.16; P = .95). There was no difference in OR or median TTP. …

… Tumor genotyping has emerged as the standard of care for patients with newly diagnosed
non–small cell lung cancer (NSCLC) because of the efficacy of targeted therapies for patients …

… , we cannot excluded the possibility that T790M was acquired while on erlotinib therapy. …
survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res …

… treatments may confound the true effect of first-line treatment on OS. In the current study, ∼40%
of erlotinib-treated … did not receive any post-study treatment. On the other hand, almost 80…

… after commencing treatment with erlotinib. First-order and high-order primary tumor texture
features reflecting image heterogeneity, standardized uptake values, metabolic tumor volume, …